Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Innova Captab Ltd - 544067 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 This is further to our intimation letter dated August 03, 2024 and pursuant to Regulation 30 read with Part A of Schedule III of the Listing Regulations, please note that the Audio Link for the earning call with the Analysts/ Investors for the Unaudited Financial Results of the Company for the quarter ended June 30, 2024 conducted through digital means on Monday, August 12, 2024 at 11:00 A.M (IST) is available at the website of the Company under the below link: https://www.innovacaptab.com/Concall2.mp3
12-08-2024
Bigul

Q1FY25 Quarterly Result Announced for Innova Captab Ltd.

 Pharmaceuticals company Innova Captab announced Q1FY25 results: Revenue from operation is Rs 294.3 crore in Q1FY25 as against Rs 233.2 crore of Q1FY24 registering a growth of 26%. The Company’s EBITDA stood at Rs 44.3 crore in Q1FY25 against Rs 32.4 crore of Q1FY24 registering a growth of 37%. Profit After Tax (PAT) stood at Rs 29.5 crore in Q1FY25 against Rs 17.6 crore of Q1FY24 registering a growth of 68% Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab said, For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters. Over the past 3-4 years, our revenue has grown at a robust growth rate. With the new Jammu facility, we are optimistic about sustaining this growth trajectory over the next few years. As a company, we remain committed to driving sustainable growth by exploring new opportunities and focusing on value-added products. The Indian pharmaceutical sector is poised for significant growth in the mid to long term, with both domestic and global MNCs are increasingly seeking reliable and sustainable suppliers like us. The foundation of Innova is their in-house research and development which helps to focus on building complex product portfolio. As a major CDMO player, Innova caters to India’s top 14 out of 15 pharmaceuticals companies and have license to manufacture products through four state of the art manufacturing facilities at Baddi - Himachal Pradesh, Dehradun - Uttarakhand and at Taloja - Maharashtra while maintaining WHO-GMP, EU-GMP, UK-MHRA and other major registrations with these facilities. By Q2FY25, the upcoming greenfield plant in Jammu is expected to be commercialized. This facility will have four production blocks: cephalosporin, penicillin, penum and BFS and will manufacture oral solid dosages, dry powder injections, dry syrup, BFS, Large Volume Parenterals and respiratory respule products. Result PDF
11-08-2024
Bigul

Innova Captab Ltd - 544067 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Submission of copy of Newspaper advertisement dated August 10, 2024 pursuant to regulation 47 of the SEBI Regulation, 2015,In respect of approval of unaudited resulted ( Standalone & Console ) of the company for the quarter ended June 30,2024.
10-08-2024
Bigul

Innova Captab Ltd - 544067 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Change Of Statutory Auditors In Sharon Bio-Medicine Limited, Material Subsidiary Of The Company

 Intimation under Regulation 30 of SEBI (LODR) Regulation,2015-Change of Statutory Auditors in Sharon Bio-Medicine Limited, Material Subsidiary of the Company.
09-08-2024
Bigul

Innova Captab Ltd - 544067 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please see enclosed herewith the investor presentation for the earning call.
09-08-2024
Bigul

Innova Captab Ltd - 544067 - Statement For Deviation(S) Or Variation(S) Pursuant To Regulation 32 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended June 30, 2024.

 Statement for deviation(s) or variations(s)pursuant to Regulation 32 of the SEBI (LODR) Regulations,2015 for the quarter ended June30,2024.
09-08-2024
Bigul

Innova Captab Ltd - 544067 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulation 30 of the SEBI Regulation, We are enclosing herewith the Press Release issued by company on Unaudited Financial results ( Standalone & Console) for the Quarter ended June 30,2024.
09-08-2024
Bigul

Innova Captab Ltd - 544067 - Quarterly Result For Q1 Of FY 2024 ( Consolidated And Standalone)

 Approval of the Unaudited (Standalone and Consolidated) financial results for quarter ended 30th June 2024 and appointment of internal auditor for FY 2025.
09-08-2024
Bigul

Innova Captab Ltd - 544067 - Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. August 09, 2024.

 Outcome of the Board Meeting held today i.e. August 09, 2024.Approval of the Un-Audited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2024 and appointment of internal auditor for FY 2025.
09-08-2024
Bigul

Innova Captab Ltd - 544067 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015
03-08-2024
Next Page
Close

Let's Open Free Demat Account